90K (Mac-2 BP) and galectins in tumor progression and metastasis
- 1 January 2002
- journal article
- review article
- Published by Springer Nature in Glycoconjugate Journal
- Vol. 19 (7-9) , 551-556
Abstract
Galectins and their ligands have been implicated in cell transformation and cancer metastasis, and found to have prognostic value. Mac-2 BP, also known as 90K, is a highly glycosylated, secreted protein extensively studied in human cancer, which binds galectin-1, galectin-3 and galectin-7. High expression levels of 90K are associated with a shorter survival, the occurrence of metastasis or a reduced response to chemotherapy in patients with different types of malignancy. The mechanisms underlying the prognostic significance of 90K and galectins in cancer are far from being understood, although they may be related to the ability of these proteins to interact and, to some extent, modulate cell-cell and cell-matrix adhesion and apoptosis. The resulting scenario is even more complex, as data have been presented that all these proteins might be associated with either a positive or a negative outcome of the patients. It is hypothesised that different galectins and galectin ligands with overlapping or opposite functions, expressed in different tumors during the different steps of the metastatic cascade might play a crucial role in tumor progression. Published in 2004.Keywords
This publication has 62 references indexed in Scilit:
- Comprehensive galectin fingerprinting in a panel of 61 human tumor cell lines by RT-PCR and its implications for diagnostic and therapeutic proceduresJournal of Cancer Research and Clinical Oncology, 2001
- The levels of expression of galectin-1, galectin-3, and the Thomsen-Friedenreich antigen and their binding sites decrease as clinical aggressiveness increases in head and neck cancersCancer, 1999
- Galectin-3 expression is induced in cirrhotic liver and hepatocellular carcinomaInternational Journal of Cancer, 1999
- Galectin-3 expression in human breast carcinoma: correlation with cancer histologic grade.International Journal of Oncology, 1998
- Circulating immunostimulatory protein 90K and soluble interleukin-2-receptor in human ovarian cancerInternational Journal of Cancer, 1996
- DECREASED EXPRESSION OF GALECTIN-3 IS ASSOCIATED WITH PROGRESSION OF HUMAN BREAST CANCERThe Journal of Pathology, 1996
- Suppression of tumor growth in vivo by local and systemic 90K level increase.1995
- Dynamic test with recombinant interferon-alpha-2b: effect on 90K and other tumour-associated antigens in cancer patients without evidence of diseaseBritish Journal of Cancer, 1993
- Measurement of a breast cancer associated antigen detected by monoclonal antibody SP-2 in sera of cancer patientsBreast Cancer Research and Treatment, 1988
- DETECTION OF ANTIGENS RECOGNIZED BY A NOVEL MONOCLONAL-ANTIBODY IN TISSUE AND SERUM FROM PATIENTS WITH BREAST-CANCER1986